• Nicox PArtner, occupation therapeutics, Ssubmits aah DCarpet AApplication for ZERVIATE in China
• ZERVIATE^® Admission and launch expected in China in 2024
• Additionally Future License income for Nicox with occupation forecast potential yearly Net sales >$100 million within 7 years

April 14, 2023 – Release at 7:30am BST
Sophia Antipolis, France

Nicox S.A FR COX))), an international ophthalmology company, announced today that its exclusive Chinese partner, Ocumension Therapeutics, has submitted a New Drug Application (NDA) to commercialize ZERVIATE^® (cetirizine ophthalmic solution), 0.24%, in China, for eye itching associated with allergic conjunctivitis. The approval process is expected to take around 12 months, leading to a possible market launch of ZERVIATE in China in 2024. Ocumension plans to manufacture ZERVIATE at its new, state-of-the-art, purpose-built manufacturing facility in Suzhou, China.

“occupation is a strong partner for Nicox, and we look forward to submitting this application for a new medicinal product after completion of an additional Chinesee Phase 3 study conducted by occupation. In addition to a broad portfolio of ophthalmology assets under development, occupation has also established a commercial operation in China which can directly incorporate ZERVIATE into its detailing activities After permission.” called Gavin Spencerboss Business Officer of Nicox. “The approval and the start from ZERVIATE in 2024, Nicox would add another revenue stream from royalties potentially annually net sales, the occupation forecasts will be over $100 million within 7 years in China. We look forward to occupation also expanding the availability of ZERVIATE to the other Southeast Asian markets for which they have rights.“

“After we have built our development pipeline, occupation see the fruits of it now pipeline when products reach commercialization. ZERVIATE is the first of these to result from our valuable collaboration with Nicox and we look forward to…